Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Ixchel Pharma logo — Pioneering the future of treatments for rare mitochondrial d...

Ixchel Pharma

Pioneering the future of treatments for rare mitochondrial diseases with repurposed drug solutions.

Founded 2004 2-10 employees Pharmaceutical

General Information

Company Name Ixchel Pharma
Founded Year 2004
Employees 2-10
Industries Pharmaceutical
Social

Get notified when Ixchel Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ixchel Pharma

Ixchel Pharma is a pharmaceutical company founded in 2004, which is committed to revolutionizing the treatment landscape for rare mitochondrial diseases through the use of repurposed drug solutions. The company's slogan, "Pioneering the future of treatments for rare mitochondrial diseases with repurposed drug solutions," encapsulates its core mission. Ixchel Pharma focuses on addressing mitochondrial diseases that currently lack FDA-approved treatments, particularly those that qualify as orphan conditions, affecting fewer than 200,000 individuals in the United States. Through the innovative approach of repurposing existing drugs, Ixchel Pharma has identified potential treatments for several severe orphan mitochondrial diseases, including Friedreich’s ataxia (FA), Mitochondrial Myopathy (MM), and Leber’s hereditary optic neuropathy (LHON). This strategic focus on leveraging already approved drugs for new indications showcases the company's commitment to delivering effective solutions within a challenging regulatory landscape. As a pharmaceutical startup targeting niche medical conditions, Ixchel Pharma presents an intriguing investment opportunity for venture capitalists. The potential to address underserved patient populations and the focused nature of its research and development efforts make it an attractive prospect for investors seeking to support groundbreaking advancements in healthcare. However, without available information regarding the company's headquarters and recent investments, further due diligence would be necessary to assess the current financial and operational status.

Taxonomy: Mitochondrial diseases, Orphan conditions, Repurposed drugs, FDA-approved treatments, Friedreich’s ataxia, Mitochondrial Myopathy, Leber’s hereditary optic neuropathy, Drug development, Rare diseases, Orphan drug development, Medical research, Healthcare innovation

No funding data available for Ixchel Pharma yet.

Get notified when Ixchel Pharma raises funding

Ixchel Pharma Alternatives & Competitors

Ixchel Pharma vs
Aceragen
Aceragen United States

Aceragen is a rare disease company striving to restore a better life for patients and families.

Private Equity
2 employees
Biotechnology, Health Care
Ixchel Pharma vs
Pretzel Therapeutics
Pretzel Therapeutics United States

Welcome to a new era in mitochondrial therapeutics

Series A
46 employees
Biotechnology, Health and Wellness
Ixchel Pharma vs
Arphio
Arphio Malta

Rare but not alone

4 employees
Health Care, Pharmaceutical

FAQ About Ixchel Pharma

Pioneering the future of treatments for rare mitochondrial diseases with repurposed drug solutions.
Ixchel Pharma was founded in 2004.
Ixchel Pharma operates in the following industries: Pharmaceutical.
Ixchel Pharma has approximately 2-10 employees.
Top alternatives and competitors to Ixchel Pharma include Aceragen, Pretzel Therapeutics, Arphio, Minovia Therapeutics , Mid-Atlantic BioTherapeutics (MABT). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ixchel Pharma and Aceragen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ixchel Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy